Abcuro
Phase 2/3Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
Founded
2016
Focus
AntibodiesBiologicsCell & Gene Therapy
About
Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
Funding History
2Total raised: $197M
Series B$155MDROIA Oncology VenturesDec 15, 2023
Series A$42MSanofi VenturesJun 15, 2021
Company Info
TypePrivate
Founded2016
LocationNewton, United States
StagePhase 2/3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile